Abstract
Neoadjuvant immunotherapy induces high pathologic response (PR) rates with prolonged relapse free survival. The PRADO trial explored omitting lymph node dissection (TLND) in patients (pts) achieving major pathologic response (MPR; ≤10% viable tumor cells) to neoadjuvant Ipilimumab (IPI) + Nivolumab (NIVO) in a single sampled lymph node. Health-Related Quality of Life (HRQoL) outcomes were evaluated in pts with and without MPR.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Paper version not known
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
